Waterloo Capital L.P. Purchases 506 Shares of Danaher Co. (NYSE:DHR)

Waterloo Capital L.P. grew its position in Danaher Co. (NYSE:DHR) by 9.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,618 shares of the conglomerate’s stock after purchasing an additional 506 shares during the quarter. Waterloo Capital L.P.’s holdings in Danaher were worth $1,404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of DHR. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the fourth quarter worth $25,000. Tsfg LLC lifted its holdings in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the second quarter valued at $25,000. nVerses Capital LLC purchased a new stake in Danaher during the second quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Danaher during the first quarter valued at $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.2 %

Shares of NYSE DHR opened at $271.90 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $201.39 billion, a price-to-earnings ratio of 46.08, a PEG ratio of 4.48 and a beta of 0.83. The stock has a 50 day moving average price of $266.50 and a 200 day moving average price of $256.89. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DHR. Robert W. Baird upped their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Bank of America upped their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Stifel Nicolaus upped their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI reduced their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.